Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Farxiga

- PMLiVE

AstraZeneca study reveals increasing number of people impacted by chronic kidney disease

CKD is a progressive condition that affects nearly 850 million people worldwide

- PMLiVE

AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer

Approximately 210,000 people worldwide are diagnosed with the disease every year

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval for paediatric patients with severe asthma

Severe eosinophilic asthma causes inflammation in the lungs and airways of patients

- PMLiVE

Everything Was Peachy at ACC 2024 in Atlanta, GA

The annual ACC meeting has officially wrapped up in Atlanta, bringing a successful conference to a close for another year.  During the conference, members of the Medscape team hosted a...

Medscape Education Global

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

- PMLiVE

AstraZeneca shares positive late-stage results for Imfinzi in small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer cases

- PMLiVE

AstraZeneca’s Voydeya granted FDA approval for rare blood disease PNH

Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis

- PMLiVE

Sharing Four Times the Impact at ACC 2024

ACC is kicking off next week in Atlanta, GA, and Medscape is heading south to join our cardiology colleagues. The Medscape team will be hosting booth #3431 on the exhibit...

Medscape Education Global

- PMLiVE

AstraZeneca’s Ultomiris receives FDA approval to treat rare autoimmune disease NMOSD

Neuromyelitis optica spectrum disorder is estimated to affect approximately 6,000 adults in the US

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

AstraZeneca’s Tagrisso combination shows promising overall survival trend in phase 3 lung cancer study

An estimated 2.4 million people globally are diagnosed with lung cancer every year

- PMLiVE

New blood test could identify individuals at highest risk of developing heart failure

Measuring NPY alongside BNP could help healthcare professionals improve diagnosis for heart patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links